Skip to main content
main-content
Erschienen in: Deutsche Dermatologie 7/2022

01.07.2022 | Fortbildung

Sonderformen der Psoriasis

Therapie meist off-label

verfasst von: Dr. med. Dietrich Barth

Erschienen in: Deutsche Dermatologie | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Auszug

Die Behandlung von Sonderformen der Psoriasis ist weitaus schwieriger als die des Plaque-Typs. Studiendaten hierzu sind oft heterogen und reichen nicht aus, um neue Indikationen etablierter Therapien zu begründen, die daher meist off-label erfolgen.
Literatur
1.
Zurück zum Zitat Mrowietz U et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10 Mrowietz U et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10
2.
Zurück zum Zitat Nast et al. Therapie der Psoriasis vulgaris. AWMF-Reg.-Nr. 013-001; 2021 Nast et al. Therapie der Psoriasis vulgaris. AWMF-Reg.-Nr. 013-001; 2021
3.
Zurück zum Zitat Bissonnette R et al. Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. J Eur Acad Dermatol Venereol 2014; 28: 1298-1305 Bissonnette R et al. Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. J Eur Acad Dermatol Venereol 2014; 28: 1298-1305
4.
Zurück zum Zitat Michaelsson G et al. The psoriasis variant palmoplantar pustulosis can be improved after cessation of smoking. J Am Acad Dermatol 2006; 54: 737-8 Michaelsson G et al. The psoriasis variant palmoplantar pustulosis can be improved after cessation of smoking. J Am Acad Dermatol 2006; 54: 737-8
5.
Zurück zum Zitat Hagforsen E et al. Expression of nicotinic receptors in the skin of patients with palmoplantar pustulosis. Br J Dermatol 2002; 146: 383-91 Hagforsen E et al. Expression of nicotinic receptors in the skin of patients with palmoplantar pustulosis. Br J Dermatol 2002; 146: 383-91
6.
Zurück zum Zitat Takahara M. Clinical outcome of tonsillectomy for palmoplantar pustulosis and etiological relationship between palmoplantar pustulosis and tonsils. Adv Otorhinolaryngol 2011; 72: 86-8 Takahara M. Clinical outcome of tonsillectomy for palmoplantar pustulosis and etiological relationship between palmoplantar pustulosis and tonsils. Adv Otorhinolaryngol 2011; 72: 86-8
7.
Zurück zum Zitat Pasch MC. Nail Psoriasis: A Review of Treatment Options. Drugs 2016; 76: 675-705 Pasch MC. Nail Psoriasis: A Review of Treatment Options. Drugs 2016; 76: 675-705
8.
Zurück zum Zitat Nakamura RC et al. Comparison of nail lacquer clobetasol efficacy at 0.05%, 1% and 8% in nail psoriasis treatment: prospective, controlled and randomized pilot study. An Bras Dermatol 2012; 87: 203-11 Nakamura RC et al. Comparison of nail lacquer clobetasol efficacy at 0.05%, 1% and 8% in nail psoriasis treatment: prospective, controlled and randomized pilot study. An Bras Dermatol 2012; 87: 203-11
9.
Zurück zum Zitat Rigopoulos D et al. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment. Dermatology 2009; 218: 338−41 Rigopoulos D et al. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment. Dermatology 2009; 218: 338−41
10.
Zurück zum Zitat Demirsoy EO et al. Effectiveness of systemic treatment agents on psoriatic nails: a comparative study. J Drugs Dermatol 2013; 12: 1039-43 Demirsoy EO et al. Effectiveness of systemic treatment agents on psoriatic nails: a comparative study. J Drugs Dermatol 2013; 12: 1039-43
11.
Zurück zum Zitat Gümüşel M et al. Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study. J Eur Acad Dermatol Venereol 2011; 25: 1080−4 Gümüşel M et al. Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study. J Eur Acad Dermatol Venereol 2011; 25: 1080−4
12.
Zurück zum Zitat Tosti A et al. Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol 2009; 145: 269−71 Tosti A et al. Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol 2009; 145: 269−71
13.
Zurück zum Zitat Rich P et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol 2016; 74: 134-42 Rich P et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol 2016; 74: 134-42
14.
Zurück zum Zitat Elewski BE et al. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial. J Am Acad Dermatol 2018; 78: 90−9 Elewski BE et al. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial. J Am Acad Dermatol 2018; 78: 90−9
15.
Zurück zum Zitat Rich P et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008; 58: 224−31 Rich P et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008; 58: 224−31
16.
Zurück zum Zitat Walsh JA et al. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial. Clinical Rheumatology 2018; 37: 3285−96 Walsh JA et al. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial. Clinical Rheumatology 2018; 37: 3285−96
17.
Zurück zum Zitat Reich K et al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol 2019; 181: 954-66 Reich K et al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol 2019; 181: 954-66
18.
Zurück zum Zitat Elewski B et al. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials. J Dermatol Treat 2022; 33: 261−5 Elewski B et al. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials. J Dermatol Treat 2022; 33: 261−5
19.
Zurück zum Zitat Wasel N et al. Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S). Dermatol Ther (Heidelb) 2020; 10: 663−70 Wasel N et al. Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S). Dermatol Ther (Heidelb) 2020; 10: 663−70
20.
Zurück zum Zitat Foley P et al. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Dermatol 2018; 154: 676−83 Foley P et al. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Dermatol 2018; 154: 676−83
21.
Zurück zum Zitat Kristensen LE et al. Effects of risankizumab on nail psoriasis in patients with active psoriatic arthritis: results from KEEPsAKE 1. J Eur Acad Dermatol Venereol 2022; 36: e389−92 Kristensen LE et al. Effects of risankizumab on nail psoriasis in patients with active psoriatic arthritis: results from KEEPsAKE 1. J Eur Acad Dermatol Venereol 2022; 36: e389−92
22.
Zurück zum Zitat Galluzzo M et al. Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis. J Clin Med 2022; 11: 2631 Galluzzo M et al. Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis. J Clin Med 2022; 11: 2631
23.
Zurück zum Zitat Yang EJ et al. The impact of genital psoriasis on quality of life: a systematic review. Psoriasis (Auckl) 2018; 8: 41−7 Yang EJ et al. The impact of genital psoriasis on quality of life: a systematic review. Psoriasis (Auckl) 2018; 8: 41−7
24.
Zurück zum Zitat Kreuter A et al. 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch Dermatol 2006; 142: 1138-43 Kreuter A et al. 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch Dermatol 2006; 142: 1138-43
25.
Zurück zum Zitat Dattola A et al. Update of calcineurin inhibitors to treat inverse psoriasis: A systematic review. Dermatol Ther 2018; 31: e12728 Dattola A et al. Update of calcineurin inhibitors to treat inverse psoriasis: A systematic review. Dermatol Ther 2018; 31: e12728
26.
Zurück zum Zitat Lebwohl M et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004; 51: 723-30 Lebwohl M et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004; 51: 723-30
27.
Zurück zum Zitat Gribetz C et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 2004; 51: 731-8 Gribetz C et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 2004; 51: 731-8
28.
Zurück zum Zitat Nisticò SP et al. Different applications of monochromatic excimer light in skin diseases. Photomed Laser Surg 2009; 27: 647−54 Nisticò SP et al. Different applications of monochromatic excimer light in skin diseases. Photomed Laser Surg 2009; 27: 647−54
29.
Zurück zum Zitat Gilbert E, Ward NL. Efficacy of botulinum neurotoxin type A for treating recalcitrant plaque psoriasis. J Drugs Dermatol 2014; 13: 1407−8 Gilbert E, Ward NL. Efficacy of botulinum neurotoxin type A for treating recalcitrant plaque psoriasis. J Drugs Dermatol 2014; 13: 1407−8
30.
Zurück zum Zitat Zanchi M et al. Botulinum toxin type-A for the treatment of inverse psoriasis. J Eur Acad Dermatol Venereol 2008; 22: 431−6 Zanchi M et al. Botulinum toxin type-A for the treatment of inverse psoriasis. J Eur Acad Dermatol Venereol 2008; 22: 431−6
31.
Zurück zum Zitat González C et al. Breaking paradigms in the treatment of psoriasis: Use of botulinum toxin for the treatment of plaque psoriasis. Dermatol Ther 2020; 33: e14319 González C et al. Breaking paradigms in the treatment of psoriasis: Use of botulinum toxin for the treatment of plaque psoriasis. Dermatol Ther 2020; 33: e14319
32.
Zurück zum Zitat Foureur N et al. Prospective aetiological study of diaper dermatitis in the elderly. Br J Dermatol 2006; 155: 941-6 Foureur N et al. Prospective aetiological study of diaper dermatitis in the elderly. Br J Dermatol 2006; 155: 941-6
33.
Zurück zum Zitat Noji S et al. Discovery of a Janus kinase inhibitor bearing a highly three-dimensional Spiro scaffold: JTE-052 (delgocitinib) as a new dermatological agent to treat inflammatory skin disorders. J Med Chem 2020; 63: 7163-85 Noji S et al. Discovery of a Janus kinase inhibitor bearing a highly three-dimensional Spiro scaffold: JTE-052 (delgocitinib) as a new dermatological agent to treat inflammatory skin disorders. J Med Chem 2020; 63: 7163-85
34.
Zurück zum Zitat Lebwohl MG et al. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. N Engl J Med 2021; 385: 2219−29 Lebwohl MG et al. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. N Engl J Med 2021; 385: 2219−29
35.
Zurück zum Zitat Kapila S et al. Vulvar psoriasis in adults and children: a clinical audit of 194 cases and review of the literature. J Low Genit Tract Dis 2012; 16: 364-71 Kapila S et al. Vulvar psoriasis in adults and children: a clinical audit of 194 cases and review of the literature. J Low Genit Tract Dis 2012; 16: 364-71
36.
Zurück zum Zitat Guglielmetti A et al. J. Inverse psoriasis involving genital skin folds: successful therapy with dapsone. Dermatol Ther 2012; 2: 15 Guglielmetti A et al. J. Inverse psoriasis involving genital skin folds: successful therapy with dapsone. Dermatol Ther 2012; 2: 15
37.
Zurück zum Zitat Tajalli M et al. Effective use of oral tofacitinib and phototherapy in a patient with concomitant alopecia areata, vitiligo, and plaque and inverse psoriasis. Clin Case Rep 2020; 8: 819-22 Tajalli M et al. Effective use of oral tofacitinib and phototherapy in a patient with concomitant alopecia areata, vitiligo, and plaque and inverse psoriasis. Clin Case Rep 2020; 8: 819-22
38.
Zurück zum Zitat Jese R et al. A case of inverse psoriasis successfully treated with adalimumab. Acta Dermatovenerol Alp Pannonica Adriat 2014; 23: 21−3 Jese R et al. A case of inverse psoriasis successfully treated with adalimumab. Acta Dermatovenerol Alp Pannonica Adriat 2014; 23: 21−3
39.
Zurück zum Zitat Campos MA et al. Inverse psoriasis treated with ustekinumab. BMJ Case Rep 2016; 2016:bcr2016215019 Campos MA et al. Inverse psoriasis treated with ustekinumab. BMJ Case Rep 2016; 2016:bcr2016215019
40.
Zurück zum Zitat Guenther G et al. Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial. Acta Derm Venereol 2020; 100: adv00006 Guenther G et al. Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial. Acta Derm Venereol 2020; 100: adv00006
41.
Zurück zum Zitat Cather JC et al. Ixekizumab provides greater improvement versus placebo on the impact of genital psoriasis on sexual activity for patients with moderate-to-severe genital psoriasis in a randomized, double-blind phase 3b clinical trial. AAD Annual Meeting 2018, P 5935 Cather JC et al. Ixekizumab provides greater improvement versus placebo on the impact of genital psoriasis on sexual activity for patients with moderate-to-severe genital psoriasis in a randomized, double-blind phase 3b clinical trial. AAD Annual Meeting 2018, P 5935
42.
Zurück zum Zitat Merola JF et al. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol 2016; 41: 486-89 Merola JF et al. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol 2016; 41: 486-89
43.
Zurück zum Zitat Patrizi A et al. Nail dystrophies, scalp and intergluteal/perianal psoriatic lesions: risk factors for psoriatic arthritis in mild skin psoriasis? G Ital Dermatol Venereol 2014; 149: 177−84 Patrizi A et al. Nail dystrophies, scalp and intergluteal/perianal psoriatic lesions: risk factors for psoriatic arthritis in mild skin psoriasis? G Ital Dermatol Venereol 2014; 149: 177−84
44.
Zurück zum Zitat Sampogna F et al. Quality of life assessment of patients with scalp dermatitis using the Italian version of the Scalpdex. Acta Derm Venereol 2014; 94: 411-4 Sampogna F et al. Quality of life assessment of patients with scalp dermatitis using the Italian version of the Scalpdex. Acta Derm Venereol 2014; 94: 411-4
45.
Zurück zum Zitat Schlager JG et al. Topical treatments for scalp psoriasis. Cochrane Database of Systematic Reviews 2016; 2: CD009687 Schlager JG et al. Topical treatments for scalp psoriasis. Cochrane Database of Systematic Reviews 2016; 2: CD009687
46.
Zurück zum Zitat Menter A et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010; 62: 114−35 Menter A et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010; 62: 114−35
47.
Zurück zum Zitat Chan CS et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009; 60: 962−71 Chan CS et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009; 60: 962−71
48.
Zurück zum Zitat Mrowietz U et al. Efficacy of dimethyl fumarate treatment for moderate-to-severe plaque psoriasis: presentation extracts from the 29th EADV virtual congress, 29-31 October 2020. Expert Rev Clin Immunol 2021; 17 (sup2): 1−11 Mrowietz U et al. Efficacy of dimethyl fumarate treatment for moderate-to-severe plaque psoriasis: presentation extracts from the 29th EADV virtual congress, 29-31 October 2020. Expert Rev Clin Immunol 2021; 17 (sup2): 1−11
49.
Zurück zum Zitat Papp K et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol 2015; 73: 37-49 Papp K et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol 2015; 73: 37-49
50.
Zurück zum Zitat Paul C et al. Efficacy and safety of apremilast, an oral phos- phodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized con- trolled trial (ESTEEM 2). Br J Dermatol 2015; 173: 1387−99 Paul C et al. Efficacy and safety of apremilast, an oral phos- phodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized con- trolled trial (ESTEEM 2). Br J Dermatol 2015; 173: 1387−99
51.
Zurück zum Zitat Fotiadou C et al. Scalp psoriasis and biologic agents: a retrospective, comparative study from a tertiary psoriasis referral centre. J Eur Acad Dermatol Venereol 2016; 30: 2091−6 Fotiadou C et al. Scalp psoriasis and biologic agents: a retrospective, comparative study from a tertiary psoriasis referral centre. J Eur Acad Dermatol Venereol 2016; 30: 2091−6
52.
Zurück zum Zitat Bagel J et al. The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol 2017; 77: 667-74 Bagel J et al. The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol 2017; 77: 667-74
53.
Zurück zum Zitat Kivelevitch D et al. Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areas. Expert Opin Pharmacother 2018; 19: 561−75 Kivelevitch D et al. Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areas. Expert Opin Pharmacother 2018; 19: 561−75
54.
Zurück zum Zitat Irmer ML et al. Psoriasis an besonderen Arealen. hautnah dermatologie 2020; 36 (6): 32−9 Irmer ML et al. Psoriasis an besonderen Arealen. hautnah dermatologie 2020; 36 (6): 32−9
55.
Zurück zum Zitat Blauvelt A et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 2017, 76: 405−17 Blauvelt A et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 2017, 76: 405−17
Metadaten
Titel
Sonderformen der Psoriasis
Therapie meist off-label
verfasst von
Dr. med. Dietrich Barth
Publikationsdatum
01.07.2022
Verlag
Springer Medizin
Erschienen in
Deutsche Dermatologie / Ausgabe 7/2022
Print ISSN: 2731-7692
Elektronische ISSN: 2731-7706
DOI
https://doi.org/10.1007/s15011-022-5023-x

Weitere Artikel der Ausgabe 7/2022

Deutsche Dermatologie 7/2022 Zur Ausgabe

Industrieforum

Nachrichten

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Dermatologie und bleiben Sie gut informiert – ganz bequem per eMail.